Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

139.18 +0.30 (+0.22%)
Official Closing Price Updated: 7:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine
In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was... 
Via TokenRing AI
Topics Artificial Intelligence Initial Public Offering
News headline image
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗
On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare. 
Via The Motley Fool
Topics Stocks
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs ↗
Via Stocktwits
News headline image
2 Top Stocks to Buy and Hold for the Long Term ↗
Both have crushed the market this year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program. 
Via Stocktwits
Topics Economy Government
News headline image
White House Readies Drug Price Deals With AbbVie, Novartis, Roche ↗
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms. 
Via Benzinga
News headline image
Salesforce Stock Rises On BTIG Buy Rating And Novartis Agentforce Deal ↗
Salesforce Inc (NYSE:CRM) shares moved higher Wednesday after BTIG kicked off coverage with a Buy rating and a $335 price target, while the company scored a major win with Novartis choosing its... 
Via Benzinga
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ↗
Novartis (NVS) offers a reliable 3.27% dividend yield, backed by strong profitability, a healthy balance sheet, and a history of consistent payouts. 
Via Chartmill
News headline image
Silver Shines as Global Tariff Storm Gathers: A Safe-Haven and Strategic Imperative in 2025
As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Novartis&#39; Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder ↗
Novartis reports Phase 3 results showing that combining ianalumab with eltrombopag significantly extends disease control and improves sustained platelet response in ITP patients. 
Via Benzinga
News headline image
Can the Vanguard International High Dividend Yield Index Fund ETF Shares Outperform Again in 2026? ↗
This low-cost international dividend ETF nearly doubled the S&P 500's return in 2025 -- but replicating that performance will require the stars to align once more. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,... 
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny
New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)... 
Via MarketMinute
Topics Intellectual Property
News headline image
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗
Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound. 
Via Stocktwits
News headline image
1 No-Brainer International Vanguard ETF to Buy Right Now for Less Than $100 ↗
A weakening dollar makes this ETF more appealing. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
2 High-Yielding ETFs That Can Bankroll Your Retirement for Years ↗
These funds offer yields that are more than three times the S&P 500 average. 
Via The Motley Fool
Topics ETFs Economy Retirement
News headline image
Why Novartis Stock Topped the Market Today ↗
The company has a brand-new product to ship to pharmacies. 
Via The Motley Fool
News headline image
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults ↗
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function improvements. 
Via Benzinga
News headline image
Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder ↗
FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition. 
Via Stocktwits
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): A Comprehensive Value Investment Analysis ↗
Novartis (NVS) appears undervalued with a low P/E ratio, strong profitability, and solid financial health, making it a compelling stock for value investors. 
Via Chartmill
News headline image
Bionique Wins Dual Golds for “Exosome + Probiotic” Breakthrough in Women’s Microbiome Health
Via Get News
News headline image
European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears
European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗
Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030. 
Via Benzinga
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
Via Investor Brand Network
News headline image
Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
From BioMedWire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.